LDR brachytherapy is commonly used for cancers of the oral cavity, oropharynx, sarcomas and prostate cancer Medium-dose rate (MDR) brachytherapy is characterized by a medium rate of dose delivery, ranging between 2 Gy·h−1 to 12 Gy·h−12
If this cut-off is to be applied to our data, we can conclude that while kallikrein gene expression is absent or low in breast cancer, medium-to-high levels of expression are found in the normal breast.
Schairer and colleagues [ 2] reported increased risk of ductal cancer with medium potency estrogen alone therapy among lean, but not obese women.
The increased risk for both ductal and lobular breast cancer with medium potency estrogen-progestin use seemed to be confined to women with BMI ≤27.
Other human cell lines with different HER2 expression were used as well: MDA-MB-453 (breast cancer origin, medium to high HER2 expression) [ 21], MCF-7 (breast cancer origin, low HER2 expression) and SJ-RH4 (rhabdomyosarcoma, null HER2 expression) [ 22].
18, 75, 76 The induction of the inflammatory response to the cancer cellconditioned medium may be due to NFκB activation via an IL-6-independent mechanism within the osteoblasts.
with L-glutamine and sodium bicarbonate, supplemented with 1% sodium pyruvate (600-110-EL, WInc . Inc)., 1% penicillin-streptomycin (450-201-EL, WInc . Inc)., and 10% fetal bovine serum (FBS, 080 150, Wisent Inc .. Prostate cancer incubation medium not exposed to cells was not capable to affect osteoclast formation (data not shown).
Patients undergoing radical cystectomy for bladder cancer in medium volume (≥10 and <16 procedures per year) institutions had 72% and 82% greater odds of 30 day in-hospital and total mortality than patients undergoing the same procedure in low volume (>2 and <10 procedures per year) institutions.
In particular, the difference was more pronounced when PMECs were cultured in cancer-conditioned medium.
All cancers were medium-differentiated adenocarcinoma.
Assuming a medium cancer home death rate population ACR of 0.278 (i.e. 278 home deaths per 1000 cancer deaths), the NNTB was 6 (95% CI 3 to 15).
